A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine

被引：0

作者：

Croop, R. ^{[1
]}

Lipton, R. B. ^{[2
]}

Kudrow, D. ^{[3
]}

Stock, D. A. ^{[1
]}

Kamen, L. ^{[1
]}

Conway, C. M. ^{[1
]}

Stock, E. G. ^{[1
]}

Coric, V. ^{[1
]}

Goadsby, P. J. ^{[4
,5
]}

机构：

[1] Biohaven Pharmaceut, New Haven, CT USA

[2] Albert Einstein Coll Med, Bronx, NY 10467 USA

[3] Calif Med Clin Headache, Santa Monica, CA USA

[4] Kings Coll Hosp London, NIHR Wellcome Trust Kings Clin Res Facil, SLaM Biomed Res Ctr, Kings Coll, London, England

[5] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA

来源：

JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

AL054

引用

页码：19 / 19

页数：1

共 50 条

[1] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V.
Goadsby, P. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 28 - 29
[2] A phase 2/3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant for the preventive treatment of migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V
Goadsby, P. J.
HEADACHE, 2021, 61 : 98 - 99
[3] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Croop, Robert
Lipton, Richard
Thiry, Alexandra
Kamen, Lisa
Coric, Vlad
Goadsby, Peter
NEUROLOGY, 2021, 96 (15)
[4] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
Lipton, R. B.
Kudrow, D.
Smith, T.
Croop, R.
Jensen, C. M.
Kamen, L.
Thiry, A.
Coric, V.
Goadsby, P. J.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 18 - 19
[5] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
Lipton, R. B.
Kudrow, D.
Smith, T.
Croop, R.
Jensen, C. M.
Kamen, L.
Thiry, A.
Coric, V.
Goadsby, P. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 27 - 28
[6] Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
Croop, Robert
Lipton, Richard B.
Kudrow, David
Stock, David A.
Kamen, Lisa
Conway, Charles M.
Stock, Elyse G.
Coric, Vladimir
Goadsby, Peter J.
LANCET, 2021, 397 (10268): : 51 - 60
[7] A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 for the Prevention of Episodic Migraine
Sun, H.
Silberstein, S.
Dodick, D. W.
Reuter, U.
Ashina, M.
Saper, J. R.
Cady, R.
Chon, Y.
Dietrich, J.
Lenz, R.
HEADACHE, 2015, 55 : 132 - 132
[8] Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Tepper, Stewart
Ashina, Messoud
Reuter, Uwe
Brandes, Jan L.
Dolezil, David
Silberstein, Stephen
Winner, Paul
Leonardi, Dean
Mikol, Daniel
Lenz, Robert
LANCET NEUROLOGY, 2017, 16 (06): : 425 - 434
[9] PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERENUMAB (AMG 334) IN CHRONIC MIGRAINE PREVENTION
Tepper, S.
Widnell, K.
Dolezil, D.
Ashina, M.
Reuter, U.
Brandes, J. Lewis
Silberstein, S.
Winner, P.
Leonardi, D.
Mikol, D.
CEPHALALGIA, 2016, 36 : 44 - 45
[10] Results of a randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of AMG 334 for the prevention of episodic migraine
Lenz, R.
Silberstein, S.
Dodick, D.
Reuter, U.
Ashina, M.
Saper, J.
Cady, R.
Chon, Y.
Dietrich, J.
Sun, H.
CEPHALALGIA, 2015, 35 : 5 - 5

← 1 2 3 4 5 →